Patent · US Active

Lectin-like oxidized LDL receptor 1 antibodies and methods of use

US9562101B2 · kind B2 · utility

6Cited by

2References

27Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Kurt Alex HELDWEIN · Belmont, US
Jennifer Brogdon · Cambridge, US
William Dole · Ipswich, US
John Trauger · Cambridge, US
Yuting Tang · Lexington, US
Julia Neugebauer · Munich, DE
Annika Schmid · Schwanau, DE

Key dates

Filing date	Jun 18, 2014
Grant date	Feb 7, 2017
Priority date	—
Expiry date	Jun 18, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.